DE&I

Executive Profiles

Executive Roundtable

Finance

Global

Industry Trends

Leadership

Legal

Market Access

Opinion

Pandemic

Patient Engagement

Pricing

R&D/Clinical Trials

Regulatory

Sales & Marketing

Strategy

Supply Chain

Sustainability

Technology

News

Pharma Pulse

Multimedia

Editorial Podcasts

Editorial Videos

Profiles in Medicine

Conferences

Conference Coverage

Conference Listing

Publications

Pharmaceutical Executive

Brand Insights

Resources

E-Books

Events

Webcasts

Whitepapers

Subscribe

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

About

Advertise

Contact Editorial

Editorial Submission Guidelines

Contact MJH Life Sciences

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

LinkedIN

Instagram

Youtube

Facebook

Threads

Soundcloud

Spotlight

Latest Executive Roundtables

Pharmaceutical Executive APEX Awards 

Topic

Sales and Marketing

1rem

Under terms of the deal, Johnson & Johnson will gain an exclusive license to the STAT6 program, with Kaken maintaining commercialization rights in Japan. 

Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers. 

Sanofi, SK Bioscience Launch Phase III Trial Program to Develop PCV21 for Pneumococcal Conjugate Vaccines

Collaboration aims to enhance PSMA-B ligand, a novel theranostic molecule in development for the treatment of prostate cancer. 

Shuttle Pharmaceuticals, UCFS Strike Sponsored Research Agreement 

Because the AI space is changing rapidly, it’s essential that companies are budgeting correctly and using their investments strategically. 

Mastering Your AI Budget for 2025 Success

Licensing deals are expected to enhance the oncology, neuroscience, and antibody drug conjugate pipelines of the three manufacturers. 

Takeda, Novartis, and Gilead Strike Separate Licensing Deals

SPIMA Launch

PE: SPIMA was funded with a strong academic foundation and support from multiple institutions. What can you tell us about these collaborative partnerships and how they help develop SPIMA’s pipeline?

SPIMA was born thanks to collaboration between two prominent institutions in the University of Montpellier in France. The first is IBMM, which specializes in the chemistry of peptides, and the second is IRMB, which specializes in the pharmacology of inflammation. Basically, scientists at IBMM designed the initial lead drug candidates, which are stable peptide, and then the scientist at IRMB were able to test them in vitro and in vivo.

They worked together for several years, and they brought the lead candidate to the pre-clinical phase through a global patent. At one point, the technology transfer office at the University of Montpellier felt that it was time to create a spinoff company in order to bring it to a clinical phase, and this is where I joined the team. We are continuing to collaborate with the technology transfer office and with the joint scientific institutions in order to progress our lead drug candidate.

Spima was founded through a collaborative effort between two academic institutions in southern France: IBMM, specializing in peptide chemistry, and IRMB, focusing on inflammation pharmacology. This partnership enabled the design of stable peptide drug candidates by IBMM and their in vitro and in vivo testing by IRMB, leading to the preclinical development and patenting of the lead candidate. The University of Montpellier's Technology Transfer Office facilitated the creation of Spima to advance these discoveries into clinical development.

Spima focuses on peptide-based immunotherapies due to their unique ability to target intracellular protein-protein interactions. Unlike small molecules, which lack specificity, or large molecules, such as antibodies, which cannot penetrate cells, peptides occupy a middle ground. Spima’s stable peptides demonstrate both cell permeability and specificity, making them ideal for addressing these challenging targets.

The company prioritizes indications with high unmet medical needs. Acute pancreatitis, with over 130,000 annual U.S. cases but no FDA-approved treatments, is a key focus. Other targets include scleroderma, a severe autoimmune disease, and cancers such as diffuse large B-cell lymphoma with MYD88 mutations, where Spima’s drug candidates have shown promising potential.

From a regulatory perspective, Spima anticipates minimal hurdles, as peptides are well-established in drug development, akin to small molecules. Recent approvals of peptide-based therapies for conditions like obesity further reinforce this outlook.

Spima emphasizes patient-centric design, guided by one of its co-founders, a physician specializing in inflammatory diseases. The company aims to integrate patient and physician insights from the earliest stages of drug design and expand these collaborations through clinical trials and advisory boards, ensuring that patient needs remain central to therapeutic development.

Videos

Mohamed Haitham Ayad, CEO, co-founder, SPIMA Therapeutics, discusses the company’s launch and how multiple institutions have supported its pipeline. 

The Launch of SPIMA Therapeutics

Finance

Latest News